Invention Grant
- Patent Title: 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
-
Application No.: US16341113Application Date: 2017-10-12
-
Publication No.: US11053234B2Publication Date: 2021-07-06
- Inventor: David Norman Deaton , Yu Guo , Ashley Paul Hancock , Christie Schulte , Barry George Shearer , Emilie Despagnet Smith , Eugene L. Stewart , Stephen Andrew Thomson
- Applicant: GlaxoSmithKline Intellectual Property Development Limited
- Applicant Address: GB Brentford
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Brentford
- Agency: Stanek Lemon Crouse & Meeks, PA
- International Application: PCT/IB2017/056320 WO 20171012
- International Announcement: WO2018/069863 WO 20180419
- Main IPC: C07D417/14
- IPC: C07D417/14 ; C07D417/12 ; C07C235/40 ; A61K9/00 ; A61K9/48 ; C07D205/04 ; C07D401/04 ; C07D239/42 ; C07D271/10 ; C07D257/06 ; C07D403/04 ; C07D277/44 ; C07D277/62 ; A61P21/00 ; A61P11/06 ; C07D215/24 ; C07D239/72 ; C07D277/64 ; C07D471/04
Abstract:
A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
Public/Granted literature
Information query
